NanoViricides, Inc. Announces Progress on Antiviral Drug NV-387 and Plans for Phase II Trials
NanoViricides, Inc. provides updates on antiviral drug NV-387 and plans for Phase II trials targeting viral infections. With superior activity against COVID, influenza, and more, the company aims to address respiratory viral infections, including COVID-19 and Long COVID.
This news matters as NanoViricides' innovative antiviral drug candidate shows promising results in preclinical studies. The progress towards Phase II trials signifies a step closer to potentially effective treatments for various viral infections, including COVID-19 and its variants.
